2210298-14-7
Chemical Structure
LCB-2122
- CAS. Nr.: 2210298-14-7
- Formula:C16H25ClN5O7P
- Molecular Weight:465.83
InChIKey: LRFQKVLLZOVBHU-ROMFRFKVSA-N
SMILES: NC1=NC(Cl)=NC2=C1N=CN2[C@@H]3O[C@H](COP(OCC)(OCC)=O)[C@@H](O)[C@@]3(C)CO
Biological Activity: LCB-2122 is an adenosine-like nucleoside analogue bearing a C2'-stereogenic all-carbon quaternary center. LCB-2122 can prevent Doxorubicin (HY-15142A)-induced cardiomyocytes apoptosis with an IC50 of 0.5 μM and prevent Imatinib (HY-15463)-induced apoptosis. LCB-2122 can activate AMPK signaling and induce the phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase (ACC). LCB-2122 can reduce Doxorubicin-induced mitochondrial damage. LCB-2122 can be used for the research of heart failure[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LCB-2122 | LCB-2122 is an adenosine-like nucleoside analogue bearing a C2'-stereogenic all-carbon quaternary center. LCB-2122 can prevent Doxorubicin (HY-15142A)-induced cardiomyocytes apoptosis with an IC50 of 0.5 μM and prevent Imatinib (HY-15463)-induced apoptosis. LCB-2122 can activate AMPK signaling and induce the phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase (ACC). LCB-2122 can reduce Doxorubicin-induced mitochondrial damage. LCB-2122 can be used for the research of heart failure. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
